This website uses cookies to enhance the user experience.
B

BIOLOGIC994 867 725

Research
Norwegian division of foreign business enterprise
Hausmanns gate 6 0186 OSLO, Norge
Services
/ Research

BIOLOGIC

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO
AP

Arne Petter Holli1956

Chairman of the board
KH

Kristin Lowzow Holli1958

Years since formation
15 years
since Dec 9, 2009
Type
Norwegian division of foreign business enterprise
VAT registered
No
Number of employees
0

Financials

Annual total result 2023
-1,521,599
NOK
Total equity 2023
-1,237,041
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
AP

Arne Petter Holli

1956

Managing Director/CEO-

Board

NameRoleShares
KH

Kristin Lowzow Holli

1958

Chairman-
AP

Arne Petter Holli

1956

Alternate Member-
B
BIOLOGIC INTERNASJONAL LTD
Information about the Company in the Home Country-

Others

NameRoleShares
B
BALANCO ACCOUNTING AS
Accountant-
Last update: Apr 13, 2023

Ownership

Shares owned by the BIOLOGIC

NameShare classNumber of sharesShare
M
MAX SIEVERT AS
Ordinary shares
220
100 %
M
MARINE INGREDIENTS SOLUTIONS AS
Ordinary shares
250
25 %
Last update: May 24, 2024

Group structure

  • BIOLOGIC
    Total operating income 2023: NOK 0
    Operating profit 2023: NOK -16,416
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
0
18,000
Annual Total Result
-1,521,599
-45,376
-437,664
Total assets
1,375,483
2,772,176
2,772,176
Total liabilities
2,612,523
2,500,678
2,444,855
Total equity
-1,237,041
327,321
327,321

P&L

Year202320222021
Total operating income
0
0
18,000
Total operating costs
16,416
17,092
445,840
Operating result
-16,416
-17,092
-427,840
Financial income/costs
-1,470,191
-41,082
-12,437
Profit before tax
-1,486,607
-58,174
-440,277
Total tax & extraordinary income/cost
34,992
-12,798
-2,613
Annual Total Result
-1,521,599
-45,376
-437,664

Balance overview

Year202320222021
Total fixed assets
1,375,000
2,772,194
19,581
Total current assets
483
244
2,752,595
Total assets
1,375,483
2,772,176
2,772,176
Short term debt
10,864
25,866
11,126
Long term debt
2,601,659
2,474,811
2,433,729
Total liabilities
2,612,523
2,500,678
2,444,855
Contributed capital
0
0
0
Retained earnings
-1,237,041
327,321
327,321
Total equity
-1,237,041
327,321
327,321
Total equity and liabilities
1,375,483
2,772,176
2,772,176

Classification

Category
Type of organization
Norwegian division of foreign business enterprise
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology